| Date Filed | Type | Description |
| 06/18/2012 |
PRN
| ARIAD Announces Updated Data From Pivotal PACE Trial of Ponatinib, its Investigational Pan-BCR-ABL Inhibitor |
| 07/14/2011 |
BW
| ARIAD to Webcast Conference Call on Second Quarter 2011 Financial Results |
| 07/05/2011 |
BW
| ARIAD Announces Presentation on Its Investigational Lung Cancer Drug Candidate, AP26113, a Dual Inhibitor of ALK and EGFR, at World Conference on Lung Cancer |
| 06/01/2011 |
BW
| ARIAD to Present at the Jefferies 2011 Global Healthcare Conference |
| 05/18/2011 |
BW
| ARIAD Announces Data Presentations and Webcast of Investor Briefing at the 2011 ASCO Annual Meeting |
| 05/04/2011 |
BW
| ARIAD Reports First Quarter 2011 Financial Results and Development Progress |
| 05/02/2011 |
BW
| ARIAD Names Norbert Riedel to Its Board of Directors |
| 04/27/2011 |
BW
| ARIAD to Webcast Conference Call on First Quarter 2011 Financial Results |
| 04/20/2011 |
PRN
| Announcement - Clontech Laboratories, Inc. Releases the iDimerize™ Cell Signaling and Expression Systems |
| 04/20/2011 |
BW
| ARIAD Announces Three Exclusive Out-License Agreements to Develop and Commercialize Its ARGENT™ Cell-Signaling Regulation Technology |
| 04/05/2011 |
BW
| ARIAD Presents New Preclinical Data on Ponatinib in Solid Tumors, Demonstrating Inhibition of All FGF Receptor Kinases |
| 03/31/2011 |
BW
| ARIAD to Present at the Leerink Swann Cancer Roundtable Conference |
| 03/29/2011 |
BW
| ARIAD to Present New Preclinical Data on Ponatinib at the American Association for Cancer Research Annual Meeting |
| 03/28/2011 |
BW
| ARIAD And MolecularMD Announce Collaboration for a Companion Diagnostic Test for The T315I BCR-ABL Mutation in Patients With CML |
| 03/21/2011 |
MW
| Smaller Biotech Companies Remain Possible Takeover Targets |
| 03/17/2011 |
BW
| ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval |
| 03/08/2011 |
BW
| ARIAD to Present at the Barclays Capital 2011 Global Healthcare Conference |
| 02/28/2011 |
BW
| ARIAD to Present at the 31st Annual Cowen Healthcare Conference |
| 02/24/2011 |
BW
| ARIAD to Present at the 2011 RBC Capital Markets' Healthcare Conference |
| 02/22/2011 |
BW
| ARIAD to Present at the CITI 2011 Global Healthcare Conference |
| 02/17/2011 |
BW
| ARIAD Reports Development Progress and Fourth Quarter and Year-End 2010 Financial Results |
| 02/10/2011 |
BW
| ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2010 Financial Results |
| 12/06/2010 |
BW
| REPEAT/ ARIAD's Ponatinib Shows Clinical Evidence of Improving Anti-Leukemic Activity in Patients with Drug-Resistant CML |
| 12/04/2010 |
BW
| ARIAD's Ponatinib Shows Clinical Evidence of Improving Anti-Leukemic Activity in Patients with Drug-Resistant CML |
| 11/29/2010 |
BW
| Updated Clinical Data on ARIAD's Investigational pan-BCR-ABL Inhibitor, Ponatinib, to Be Presented at Annual American Society of Hematology Meeting |
| 11/10/2010 |
BW
| ARIAD to Present at the Lazard Capital Markets 7th Annual Healthcare Conference |
| 11/09/2010 |
BW
| ARIAD Reports Third Quarter 2010 Financial Results and Development Progress |
| 11/01/2010 |
BW
| ARIAD to Webcast Conference Call on Third Quarter 2010 Financial Results |
| 10/26/2010 |
BW
| ARIAD Announces Pricing of Public Offering of Common Stock |
| 10/25/2010 |
BW
| ARIAD Announces Proposed Public Offering of Common Stock |
| 10/15/2010 |
BW
| Ariad to Present at the 17th Annual NewsMakers in the Biotech Industry Conference |
| 09/28/2010 |
BW
| ARIAD to Present at the Jefferies Global SpecPharma and European Healthcare Conference |
| 09/13/2010 |
BW
| ARIAD Announces Initiation of Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia |
| 09/10/2010 |
BW
| ARIAD to Hold Conference Call on Monday, September 13, 2010 at 9:00 AM (ET) |
|